非小细胞肺癌免疫治疗进展
Progress in Immunotherapy of Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2024.141208, PDF,   
作者: 赵雯黎*：宝鸡市凤翔区医院呼吸内科，陕西 宝鸡；张彤尧, 高文胜#：宝鸡市凤翔区医院外一科，陕西 宝鸡
关键词: 非小细胞肺癌；免疫治疗；不良反应；帕博利珠单抗；Non-Small Cell Lung Cancer； Immunotherapy； Adverse Reactions； Pembrolizumab
摘要: 在世界范围内，肺癌是癌症相关死亡的最常见原因。在肺癌的常见类型中，非小细胞肺癌(Non-Small Cell Lung Cancer, NSCLC)占到了所有肺癌类型的85%，手术是其早期病变的主要治疗手段，但是单纯手术治疗后局部复发及转移复发率极高。不能手术切除的非小细胞肺癌曾经一般使用化学治疗、放射治疗等方案，但是收获的效果有限。在过去的20年里，非小细胞肺癌(NSCLC)的分子靶向治疗和免疫治疗显著地改善了疗效，特别是免疫治疗在非小细胞肺癌的治疗中已经成为标准治疗方法之一。本文就目前关于非小细胞肺癌免疫治疗进展作一综述。
Abstract: Lung cancer stands as the leading cause of cancer-related mortality all over the word. Non-Small Cell Lung Cancer (NSCLC), among the common lung cancer types, constitutes 85% of all cases. While surgery remains the primary treatment for early-stage lesions, the post-surgical rates of local re-currence and metastasis are notably high. Chemotherapy and radiotherapy are conventional ap-proaches for unresectable NSCLC; however, their efficacy is often limited. Over the past two decades, molecular targeted therapy and immunotherapy have markedly enhanced the outcomes for NSCLC. Notably, immunotherapy has emerged as a standard treatment modality for NSCLC. This paper re-views the advancements in immunotherapy for non-small cell lung cancer.
文章引用：赵雯黎, 张彤尧, 高文胜. 非小细胞肺癌免疫治疗进展[J]. 临床医学进展, 2024, 14(1): 1445-1452. https://doi.org/10.12677/ACM.2024.141208

参考文献

[1] Wang, M., Herbst, R.S. and Boshoff, C. (2021) Toward Personalized Treatment Approaches for Non-Small-Cell Lung Cancer. Nature Medicine, 27, 1345-1356. [Google Scholar] [CrossRef] [PubMed]
[2] Duma, N., Santa-na-Davila, R. and Molina, J.R. (2019) Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treat-ment. Mayo Clinic Proceedings, 94, 1623-1640. [Google Scholar] [CrossRef] [PubMed]
[3] Bray, F., Fer-lay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[4] Suda, K., Sato, K., Mizuuchi, H., Kobayashi, Y., Shimoji, M., Tomizawa, K., Takemoto, T., Iwasaki, T., Sakaguchi, M. and Mitsudomi, T. (2014) Recent Evidence, Advances, and Current Practices in Surgical Treatment of Lung Cancer. Respiratory Investigation, 52, 322-329. [Google Scholar] [CrossRef] [PubMed]
[5] 韩莎莎, 等. 转移性非小细胞肺癌系统治疗[J]. 西北国防医学杂志, 2021, 42(5): 407-412.
[6] 郭超, 张家齐, 李单青. 非小细胞肺癌新辅助免疫治疗进展[J]. 中国肺癌杂志, 2022, 25(7): 524-533.
[7] Nagano, T., Tachihara, M. and Nishimura, Y. (2019) Molecular Mechanisms and Tar-geted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 19, 595-630. [Google Scholar] [CrossRef] [PubMed]
[8] Larkin, J., Minor, D., D’Angelo, S., Neyns, B., et al. (2018) Overall Survival in Patients with Advanced Melanoma Who Received Nivolumab versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology, 36, 383-390. [Google Scholar] [CrossRef] 
[9] Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., et al. (2017) Atezolizumab versus Docetaxel in Patients with Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial. The Lancet, 389, 255-265. [Google Scholar] [CrossRef] 
[10] Brahmer, J.R., Lee, J.S., Ciuleanu, T.E., Bernabe Caro, R., et al. (2023) Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab versus Chemotherapy as First-Line Treat-ment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. Journal of Clinical Oncology, 41, 1200-1212. [Google Scholar] [CrossRef] 
[11] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[12] Cao, W., Chen, H.D., Yu, Y.W., et al. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal (England), 134, 783-791. [Google Scholar] [CrossRef] 
[13] Chen, P., Liu, Y., Wen, Y. and Zhou, C. (2022) Non-Small Cell Lung Cancer in China. Cancer Communications (London), 42, 937-970. [Google Scholar] [CrossRef] [PubMed]
[14] Schreiber, R.D., Old, L.J. and Smyth, M.J. (2011) Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science, 331, 1565-1570. [Google Scholar] [CrossRef] [PubMed]
[15] Chen, D.S. and Mellman, I. (2013) Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity, 39, 1-10. [Google Scholar] [CrossRef] [PubMed]
[16] Socinski, M.A., Jotte, R.M., Cappuzzo, F., Nishio, M., et al. (2023) Association of Immune-Related Adverse Events with Efficacy of Atezolizumab in Patients with Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncology, 9, 527-535. [Google Scholar] [CrossRef] [PubMed]
[17] Zhou, F., Qiao, M. and Zhou, C. (2021) The Cutting-Edge Pro-gress of Immune-Checkpoint Blockade in Lung Cancer. Cellular & Molecular Immunology, 18, 279-293. [Google Scholar] [CrossRef] [PubMed]
[18] Kennedy, L.B. and Salama, A. (2020) A Review of Cancer Im-munotherapy Toxicity. CA: A Cancer Journal for Clinicians, 70, 86-104. [Google Scholar] [CrossRef] [PubMed]
[19] Ai, L., Xu, A. and Xu, J. (2020) Roles of PD-1/PD-L1 Pathway: Signal-ing, Cancer, and beyond. Advances in Experimental Medicine and Biology, 1248, 33-59. [Google Scholar] [CrossRef] [PubMed]
[20] Han, Y., Liu, D. and Li, L. (2020) PD-1/PD-L1 Pathway: Cur-rent Researches in Cancer. American Journal of Cancer Research, 10, 727-742.
[21] Hosseini, A., Gharibi, T., Marofi, F., et al. (2020) CTLA-4: From Mechanism to Autoimmune Therapy. International Immunopharmacology, 80, Article ID: 106221. [Google Scholar] [CrossRef] [PubMed]
[22] 李浩洋, 王敬慧. 晚期非小细胞肺癌免疫治疗进展[J]. 中国肺癌杂志, 2021, 24(2): 131-140.
[23] Patel, S.A. and Weiss, J. (2020) Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy. Clinics in Chest Medicine, 41, 237-247. [Google Scholar] [CrossRef] [PubMed]
[24] Vansteenkiste, J., Wauters, E., Reymen, B., et al. (2019) Current Status of Immune Checkpoint Inhibition in Early-Stage NSCLC. Annals of Oncology, 30, 1244-1253. [Google Scholar] [CrossRef] [PubMed]
[25] Vaidya, P. and Cohen, E.E.W. (2019) Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research, 25, 4592-4602. [Google Scholar] [CrossRef] 
[26] Garon, E.B., Rizvi, N.A., Hui, R., et al. (2015) Pembroli-zumab for the Treatment of Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 372, 2018-2028. [Google Scholar] [CrossRef] 
[27] Herbst, R.S., Baas, P., Kim, D.W., Felip, E., et al. (2016) Pem-brolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. The Lancet, 387, 1540-1550. [Google Scholar] [CrossRef] 
[28] Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833. [Google Scholar] [CrossRef] 
[29] Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. (2019) Up-dated Analysis of KEYNOTE-024: Pembrolizumab versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 37, 537-546. [Google Scholar] [CrossRef] 
[30] Mok, T.S.K., Wu, Y.L., Kudaba, I., Kowalski, D.M., et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830. [Google Scholar] [CrossRef] 
[31] Brahmer, J., Reckamp, K.L., Baas, P., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135. [Google Scholar] [CrossRef] 
[32] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England Journal of Medicine, 373, 23-34. [Google Scholar] [CrossRef] 
[33] Nghiem, P.T., Bhatia, S., Lipson, E.J., et al. (2016) PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. The New England Journal of Medicine, 374, 2542-2552. [Google Scholar] [CrossRef] 
[34] Powles, T., O’Donnell, P.H., Massard, C., et al. (2017) Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results from a Phase 1/2 Open-Label Study. JAMA Oncology, 3, e172411. [Google Scholar] [CrossRef] [PubMed]
[35] Fehrenbacher, L., Spira, A., Ballinger, M., et al. (2016) Atezoli-zumab versus Docetaxel for Patients with Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial. The Lancet, 387, 1837-1846. [Google Scholar] [CrossRef] 
[36] Weinstock, C., Khozin, S., Suzman, D., et al. (2017) U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer. Clinical Cancer Research, 23, 4534-4539. [Google Scholar] [CrossRef] 
[37] Weinmann, S.C. and Pisetsky, D.S. (2019) Mechanisms of Immune-Related Adverse Events during the Treatment of Cancer with Immune Checkpoint Inhibitors. Rheumatology (Oxford), 58, vii59-vii67. [Google Scholar] [CrossRef] [PubMed]
[38] Xu, C., Chen, Y.P., Du, X.J., et al. (2018) Comparative Safety of Immune Checkpoint Inhibitors in Cancer: Systematic Review and Network Meta-Analysis. BMJ, 363, k4226. [Google Scholar] [CrossRef] [PubMed]
[39] Abdel-Wahab, N., Shah, M., Lopez-Olivo, M.A., et al. (2018) Use of Im-mune Checkpoint Inhibitors in the Treatment of Patients with Cancer and Preexisting Autoimmune Disease: A Systematic Review. Annals of Internal Medicine, 168, 121-130. [Google Scholar] [CrossRef] 
[40] Ramos-Casals, M., Brahmer, J.R., Callahan, M.K., et al. (2020) Immune-Related Adverse Events of Checkpoint Inhibitors. Nature Reviews Disease Primers, 6, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[41] John, T., Sakai, H., Ikeda, S., Cheng, Y., et al. (2022) First-Line Nivolumab plus Ipilimumab Combined with Two Cycles of Chemotherapy in Ad-vanced Non-Small Cell Lung Cancer: A Subanalysis of Asian Patients in CheckMate 9LA. International Journal of Clinical Oncology, 27, 695-706. [Google Scholar] [CrossRef] [PubMed]
[42] Tang, Q., Chen, Y., Li, X., Long, S., et al. (2022) The Role of PD-1/PD-L1 and Application of Immune-Checkpoint Inhibitors in Human Cancers. Frontiers in Immunology, 13, Article ID: 964442. [Google Scholar] [CrossRef] [PubMed]
[43] Planchard, D., Popat, S., Kerr, K., et al. (2018) Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 29, iv192-iv237. [Google Scholar] [CrossRef] [PubMed]
[44] Zhang, Y.X., Zhou, H.Q. and Zhang, L. (2018) Which Is the Optimal Immunotherapy for Advanced Squamous Non-Small-Cell Lung Cancer in Combination with Chemotherapy: Anti-PD-1 or Anti-PD-L1? The Journal for ImmunoTherapy of Cancer, 6, 135. [Google Scholar] [CrossRef] [PubMed]
[45] Cascone, T., William, W.N., Weissferdt, A., et al. (2021) Neoad-juvant Nivolumab or Nivolumab plus Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Randomized NEOSTAR Trial. Nature Medicine, 27, 504-514. [Google Scholar] [CrossRef] [PubMed]

为你推荐